A. Doshi

IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy

L. Billings, H. Watada, Bue F Ross Agner, 2019, Diabetes Therapy.

Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin ; DUALVII Randomized Clinical Trial

H. Rodbard, L. Billings, A. Doshi, 2022 .

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

H. Rodbard, L. Billings, A. Doshi, 2018, Diabetes Care.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

148-OR: IDegLira Improves Glycemic Control in Japanese Patients with Type 2 Diabetes (T2D) Uncontrolled on Premixed Insulin Therapy

L. Billings, H. Watada, A. Doshi, 2019, Diabetes.

IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy

L. Billings, A. Doshi, M. Ranthe, 2019, Diabetes, obesity & metabolism.

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin

K. Begtrup, T. Vilsbøll, I. Lingvay, 2019, Diabetic medicine : a journal of the British Diabetic Association.